Global News

Kalytera identifies sites for planned GvHD clinical trials

Wednesday, April 26, 2017

Kalytera Therapeutics, a clinical-stage biopharmaceutical company developing next-generation cannabinoid- derived therapeutics, has developed the multicenter location component of the plan for the proposed clinical trials to evaluate cannabidiol (CBD) for the prevention and treatment of Graft versus Host Disease (GvHD). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

[Read More]

ACRP, DrugDev partner to increase visibility of clinical researcher and site profiles

Wednesday, April 26, 2017

The Association of Clinical Research Professionals (ACRP) and DrugDev announced a partnership to radically decrease clinical trial investigator burden. The two organizations have partnered together to offer ACRP clinical researchers and site staff members online profiles visible to premier pharma companies and CROs. These companies and CROs represent more than one-third of all clinical trials today and will support ACRP members’ needs for faster, more efficient site selection. This achievement is made possible by the DrugDev Profiles System, which uses the DrugDev Golden Number to match and master site facilities and personnel information.

[Read More]

Immune Pharmaceuticals to restructure

Tuesday, April 25, 2017

Immune Pharmaceuticals, a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced a major corporate restructuring with the objective of prioritizing and segregating its R&D efforts on a focused set of products in inflammatory disease and dermatology and strengthening its financial position. 

[Read More]